Experience of using an angiogenesis inhibitor aflibercept in patients with complicated cataract and newly diagnosed diabetic macular edema
Aspirantskiy Vestnik Povolzhiya · 15.05.2026 · 26 (2) · 21-27
DOI: 10.35693/avp698474 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aspirantskiy Vestnik Povolzhiya, online erschienen am 15.05.2026. Verfasst von Natalya Yu. Belousova und 3 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim: comparative assessment of the effectiveness of intravitreal use of anti-VEGF drug Aflibercept before Phaco+IOL and in combination with its intraoperative injection in patients with complicated cataract and newly diagnosed diabetic macular edema (DME). Material and methods. 64 patients with non-proliferative diabetic retinopathy, complicated cataract and newly diagnosed DME were treated. 2 groups of patients were formed depending on the method of anti-angiogenic therapy. The patients of the first group were given 3 loading injections of Aflibercept before Phaco+IOL. 1 injection was performed in the second group 1 month before cataract surgery and intraoperatively. Best-corrected visual acuity (BCVA) assessment and central retinal thickness (CRT) measurement were done in a week and a month after cataract surgery.
Results
Recurrence of DME was not diagnosed in 75% cases of the first group with an increase in average BCVE by 61.54% and CRT by 8.37% in a week after cataract surgery. Average BCVE raise was 53.68% и CRT increased by 26.5% in 1 month after Phaco+IOL. The second group demonstrated recurrence of DME in 43.75% cases. In 1 week after Phaco+IOL average increase in BCVE equaled 59.62% with CRT raise by 40%. A month later BCVA increase decreased to 32.26% with CRT raise to 53.54%. All the patients were continued anti-angiogenic therapy to five loading doses.
Conclusion
The results obtained confirmed higher efficacy of 3 loading injections of Aflibercept before Phaco+IOL in comparison with its single injection before cataract removal and intraoperatively for prevention DME recurrence in the postoperative period.
Zitieren
APA
Belousova, N. Y., Sokolova, T. P., Smetankin, I. G., & Mironova, S. I. (2026). Experience of using an angiogenesis inhibitor aflibercept in patients with complicated cataract and newly diagnosed diabetic macular edema. Aspirantskiy Vestnik Povolzhiya, 26(2), 21-27. https://doi.org/10.35693/avp698474
Vancouver
Belousova NY, Sokolova TP, Smetankin IG, Mironova SI. Experience of using an angiogenesis inhibitor aflibercept in patients with complicated cataract and newly diagnosed diabetic macular edema. Aspirantskiy Vestnik Povolzhiya. 2026;26(2):21-27. doi:10.35693/avp698474
BibTeX
@article{Belousova2026,
author = {Belousova, Natalya Yu. and Sokolova, Tatyana P. and Smetankin, Igor G. and Mironova, Svetlana I.},
title = {Experience of using an angiogenesis inhibitor aflibercept in patients with complicated cataract and newly diagnosed diabetic macular edema},
journal = {Aspirantskiy Vestnik Povolzhiya},
year = {2026},
volume = {26},
number = {2},
pages = {21--27},
doi = {10.35693/avp698474}
}
EUVIMED